Eli Lilly and Co. (NYSE:LLY) – Stock analysts at Jefferies Group raised their FY2017 earnings per share (EPS) estimates for Eli Lilly and in a report issued on Thursday. Jefferies Group analyst J. Holford now anticipates that the brokerage will post earnings of $4.26 per share for the year, up from their prior forecast of $4.12. Jefferies Group currently has a “Buy” rating and a $105.00 price objective on the stock. Jefferies Group also issued estimates for Eli Lilly and’s FY2018 earnings at $4.49 EPS and FY2020 earnings at $7.10 EPS.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.86. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. The business earned $5.40 billion during the quarter, compared to analyst estimates of $5.14 billion. During the same quarter in the previous year, the firm posted $0.90 EPS. The business’s revenue for the quarter was up 8.6% compared to the same quarter last year.
Several other research firms have also recently weighed in on LLY. Argus boosted their price objective on Eli Lilly and from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Tuesday, August 2nd. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $92.00 price objective for the company in a research report on Friday, August 5th. Leerink Swann reissued a “buy” rating on shares of Eli Lilly and in a research report on Sunday, June 26th. BMO Capital Markets reissued an “outperform” rating and set a $94.00 price objective on shares of Eli Lilly and in a research report on Tuesday, September 27th. Finally, Goldman Sachs Group Inc. raised Eli Lilly and from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $89.00 to $95.00 in a research report on Tuesday, September 27th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $97.06.
Eli Lilly and (NYSE:LLY) opened at 79.27 on Monday. The firm has a market cap of $83.84 billion, a price-to-earnings ratio of 34.17 and a beta of 0.17. Eli Lilly and has a 52-week low of $67.88 and a 52-week high of $88.16. The company’s 50-day moving average price is $79.73 and its 200-day moving average price is $77.79.
In other news, Director Jackson P. Tai acquired 2,560 shares of the firm’s stock in a transaction on Friday, August 12th. The shares were purchased at an average cost of $80.42 per share, for a total transaction of $205,875.20. Following the transaction, the director now owns 42,110 shares of the company’s stock, valued at $3,386,486.20. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Donald A. Zakrowski sold 1,213 shares of the stock in a transaction on Thursday, July 28th. The shares were sold at an average price of $83.16, for a total value of $100,873.08. Following the completion of the transaction, the insider now owns 1,300 shares in the company, valued at $108,108. The disclosure for this sale can be found here. 0.20% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in LLY. Vanguard Group Inc. increased its position in Eli Lilly and by 2.2% in the second quarter. Vanguard Group Inc. now owns 63,236,677 shares of the company’s stock worth $4,979,889,000 after buying an additional 1,350,329 shares during the period. Franklin Resources Inc. increased its position in Eli Lilly and by 2.5% in the second quarter. Franklin Resources Inc. now owns 28,430,876 shares of the company’s stock worth $2,238,939,000 after buying an additional 685,898 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in Eli Lilly and by 1.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 26,674,046 shares of the company’s stock worth $2,100,581,000 after buying an additional 289,681 shares during the period. JPMorgan Chase & Co. increased its position in Eli Lilly and by 3.0% in the second quarter. JPMorgan Chase & Co. now owns 23,184,616 shares of the company’s stock worth $1,825,790,000 after buying an additional 668,184 shares during the period. Finally, BlackRock Fund Advisors increased its position in Eli Lilly and by 2.8% in the second quarter. BlackRock Fund Advisors now owns 17,206,391 shares of the company’s stock worth $1,355,003,000 after buying an additional 475,012 shares during the period. Hedge funds and other institutional investors own 74.99% of the company’s stock.
About Eli Lilly and